STOCK TITAN

NRIX director Form 3 shows no beneficial ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Nurix Therapeutics (NRIX) filed a Form 3 reporting the initial beneficial ownership status of director Roger Dansey following an event dated 11/06/2025. The filing states that no securities are beneficially owned. The form was filed by one reporting person and signed by an attorney-in-fact under a Power of Attorney.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
DANSEY ROGER D

(Last) (First) (Middle)
C/O NURIX THERAPEUTICS, INC.
1700 OWENS STREET

(Street)
SAN FRANCISCO CA 94158

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/06/2025
3. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney
No securities are beneficially owned.
/s/ Daniel Burbach, as Attorney-in-Fact for Roger Dansey 11/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Nurix Therapeutics (NRIX) report in this Form 3?

The Form 3 states that director Roger Dansey has no securities beneficially owned.

Who is the reporting person on NRIX’s Form 3?

The reporting person is Roger Dansey, identified as a Director.

What is the date of the event requiring the Form 3?

The event date is 11/06/2025.

Is the filing made by one person or a group?

It is filed by one reporting person.

Does the Form 3 list any non-derivative or derivative holdings?

No. The remarks indicate No securities are beneficially owned.

Who signed the Form 3 and under what authority?

It was signed by /s/ Daniel Burbach as Attorney-in-Fact under a Power of Attorney.
Nurix Therapeutics, Inc.

NASDAQ:NRIX

NRIX Rankings

NRIX Latest News

NRIX Latest SEC Filings

NRIX Stock Data

1.92B
98.39M
1.43%
115.02%
16.76%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO